LENZ Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 5, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 5, 2025

LENZ$4.10-4.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations And Comprehensive Loss

(in thousands, except share and per share data)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Revenue:
License revenue	$12,500	$—	$17,500	$—
Total revenue	12,500	—	17,500	—
Operating expenses:
Selling, general and administrative	27,596	6,494	51,505	19,452
Research and development	3,791	6,451	18,670	23,933
Total operating expenses	31,387	12,945	70,175	43,385
Loss from operations	(18,887)	(12,945)	(52,675)	(43,385)
Other income:
Other (expense) income	(14)	(6)	174	281
Interest income	2,201	2,736	6,770	5,987
Total other income, net	2,187	2,730	6,944	6,268
Net loss before income taxes	(16,700)	(10,215)	(45,731)	(37,117)
Income tax expense	—	—	500	—
Net loss	$(16,700)	$(10,215)	$(46,231)	$(37,117)
Other comprehensive loss:
Unrealized gain on marketable securities	189	585	31	517
Comprehensive loss	$(16,511)	$(9,630)	$(46,200)	$(36,600)
Net loss per share, basic and diluted	$(0.59)	$(0.38)	$(1.65)	$(1.93)
Weighted-average common shares outstanding, basic and diluted (1)	28,540,519	27,172,330	28,052,279	19,195,399

(1)See Note 2 for further information on weighted-average common shares outstanding.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.